We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Impact of Social Proximity on Conversion to Generic Prescription Medications

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01251419
First Posted: December 1, 2010
Last Update Posted: May 18, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
National Bureau of Economic Research, Inc.
  Purpose
The goal of this project is to understand the effects of receiving peer information on individuals' conversion rates from brand name prescription medication to generic prescription medication.

Condition Intervention
Conversion From Brand Name to Generic Medication Other: Social Proximity and Conversion to Generic Medications

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Health Services Research
Official Title: The Impact of Social Proximity on Conversion to Generic Prescription Medications

Further study details as provided by National Bureau of Economic Research, Inc.:

Primary Outcome Measures:
  • Conversion from Brand Name to Generic Prescription Medication [ Time Frame: One month to one year after the intervention. ]
    We will measure conversion rates of employees from brand name to generic prescription medication by treatment arm.


Secondary Outcome Measures:
  • Union Status and Conversation to Generic Medication [ Time Frame: One month to one year after the intervention. ]
    We will see how union affiliation affects the employee conversion rates from brand name to prescription medication by treatment arm.


Enrollment: 10000
Study Start Date: March 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Testimonial and Union Arm
The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
Other: Social Proximity and Conversion to Generic Medications
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
Experimental: Control
The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication.
Other: Social Proximity and Conversion to Generic Medications
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
Experimental: Testimonial Treatment Arm
The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial.
Other: Social Proximity and Conversion to Generic Medications
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.

Detailed Description:

At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.

The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication. The testimonial treatment arm will receive the exact same letter, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial. The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Employee of a company that uses Express Scripts as its pharmacy benefits manager.
  • Employee at a company with predominantly union employees.
  • Currently taking a brand name medication with an exact generic equivalent.

Exclusion Criteria:

  • Employees on any psychological prescription medication.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01251419


Locations
United States, Missouri
Express Scripts
St. Louis, Missouri, United States, 63121
Sponsors and Collaborators
National Bureau of Economic Research, Inc.
National Institute on Aging (NIA)
Investigators
Principal Investigator: David Laibson, Ph.D National Bureau of Economic Research
  More Information

Responsible Party: National Bureau of Economic Research, Inc.
ClinicalTrials.gov Identifier: NCT01251419     History of Changes
Other Study ID Numbers: 0002
P30AG034532 ( U.S. NIH Grant/Contract )
First Submitted: November 30, 2010
First Posted: December 1, 2010
Last Update Posted: May 18, 2012
Last Verified: May 2012

Keywords provided by National Bureau of Economic Research, Inc.:
Generic Medication
Brand Name Medication
Conversion Rates
Social Proximity
Behavioral Economics